Scarica l'app Stockscreener
18.47
3.82%
0.68
Dopo l'orario di chiusura:
18.36
-0.11
-0.60%
Precedente Chiudi:
$17.79
Aprire:
$17.87
Volume 24 ore:
2.48M
Relative Volume:
2.08
Capitalizzazione di mercato:
$1.84B
Reddito:
-
Utile/perdita netta:
$-183.79M
Rapporto P/E:
-8.9266
EPS:
-2.0691
Flusso di cassa netto:
$-131.84M
1 W Prestazione:
+4.71%
1M Prestazione:
+4.82%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$17.82
$19.06
Intervallo di 1 settimana:
$17.25
$19.67
Portata 52W:
$14.62
$19.67
Definium Therapeutics Inc Stock (DFTX) Company Profile
Nome
Definium Therapeutics Inc
Settore
Industria
Telefono
212-220-6633
Indirizzo
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
18.47 | 1.77B | 0 | -183.79M | -131.84M | -2.0691 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-01-30 | Iniziato | Jefferies | Buy |
| 2025-10-13 | Iniziato | Needham | Buy |
| 2025-08-04 | Ripresa | Oppenheimer | Outperform |
| 2025-01-28 | Iniziato | Evercore ISI | Outperform |
| 2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-14 | Ripresa | Leerink Partners | Outperform |
| 2024-07-24 | Iniziato | ROTH MKM | Buy |
| 2024-05-29 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-15 | Iniziato | Leerink Partners | Outperform |
| 2023-12-05 | Iniziato | Canaccord Genuity | Buy |
| 2022-12-09 | Ripresa | ROTH Capital | Buy |
| 2022-11-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-08-26 | Iniziato | Oppenheimer | Outperform |
| 2022-08-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-05-04 | Iniziato | ROTH Capital | Buy |
| 2021-06-28 | Iniziato | Maxim Group | Buy |
Mostra tutto
Definium Therapeutics Inc Borsa (DFTX) Ultime notizie
A Look At Definium Therapeutics (DFTX) Valuation After Its Recent Name Change And Share Price Momentum - Yahoo Finance
Definium Therapeutics Inc (DFTX) Says Cash Enough to Fund Operations into 2028 - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Biotech Firm Developing LSD-Based Psychiatric Treatments Moves to Dismiss Trade Secrets Lawsuit, Calls Claims by Former Clinical Trial Vendor Legally Deficient - USA Herald
A Look At Definium Therapeutics (DFTX) Valuation After Strong Recent Share Price Momentum - Sahm
Definium Therapeutics (NASDAQ:DFTX) Sets New 12-Month HighHere's Why - MarketBeat
Definium Therapeutics stock hits 52-week high at 19.66 USD By Investing.com - Investing.com South Africa
Definium Therapeutics stock hits 52-week high at 19.66 USD - Investing.com
Definium Therapeutics Teases 3 Key DT-120 Data Readouts This Year, Highlights De-Risked Phase 3 Design - MarketBeat
Is It Too Late To Consider Definium Therapeutics (DFTX) After A 163% One Year Surge? - Sahm
Superstring Capital's Definium Therapeutics Investment: Q4 2025 PositionNews and Statistics - IndexBox
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names - AOL.com
DFTX: Definium Therapeutics, Inc.Detailed Earnings Estimates - Zacks Investment Research
DFTX: Pivotal phase III data for DT-120 in GAD and MDD expected this year, targeting broad market impact - TradingView
Definium Therapeutics, Inc. (NASDAQ:DFTX) Q4 2025 earnings call transcript - MSN
Definium Therapeutics stock hits 52-week high at 18.71 USD By Investing.com - Investing.com Nigeria
Boxer Capital Management LLC Takes Position in Definium Therapeutics, Inc. $DFTX - MarketBeat
Definium Therapeutics Teases Phase III DT120 Data for Anxiety, Depression at Leerink Conference - MarketBeat
Commodore Capital LP Lowers Holdings in Definium Therapeutics, Inc. $DFTX - MarketBeat
Ally Bridge Group NY LLC Sells 364,728 Shares of Definium Therapeutics, Inc. $DFTX - MarketBeat
Rosalind Advisors Inc. Has $8.84 Million Holdings in Definium Therapeutics, Inc. $DFTX - MarketBeat
Definium Therapeutics (DFTX) Stock Analysis Report | Financials & Insights - Benzinga Japan
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), Integer Holdings (ITGR) and Edgewise Therapeutics (EWTX) - The Globe and Mail
DFTX: Phase III data for DT120 in GAD and MDD expected in 2024, targeting major unmet needs - TradingView
DFTX: Three pivotal data readouts for GAD and MDD expected in 2024, with strong Phase II results - TradingView
Definium Therapeutics, Inc. (NASDAQ:DFTX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Definium Therapeutics stock hits 52-week high at 18.71 USD - Investing.com Australia
Definium Therapeutics (NASDAQ:DFTX) Sets New 1-Year HighHere's Why - MarketBeat
Definium Therapeutics Announces New Employee Inducement Grants - National Today
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions - Investing News Network
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions (2026-03-09) - Seeking Alpha
How Definium’s Widening 2025 Loss Will Impact Definium Therapeutics (DFTX) Investors - simplywall.st
Royce & Associates LP Invests $955,000 in Definium Therapeutics, Inc. $DFTX - MarketBeat
Equities Analysts Set Expectations for DFTX Q1 Earnings - Defense World
Q1 EPS Forecast for Definium Therapeutics Cut by Analyst - MarketBeat
Evercore ISI Sticks to Their Buy Rating for Definium Therapeutics (DFTX) - The Globe and Mail
A Look At Definium Therapeutics (DFTX) Valuation As Wider Full Year Loss Refocuses Investor Expectations - simplywall.st
Number of shareholders of Definium Therapeutics, Inc. – NASDAQ:DFTX - TradingView
Definium Therapeutics Inc: DT120's robust efficacy and rapid adoption potential position it as a transformative psychiatric therapy - TradingView
Definium Therapeutics Inc: DT120 demonstrated unprecedented efficacy in GAD and MDD, with broad adoption anticipated - TradingView
DFTX: HC Wainwright & Co. Raises Price Target to $70 | DFTX Stoc - GuruFocus
Definium Therapeutics (NASDAQ:DFTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Definium Therapeutics Advances DT120 ODT As Trials And Valuation Gain Focus - simplywall.st
Definium Therapeutics Weighs Breakthrough Status Against Valuation And Trial Risks - Yahoo Finance
DFTX Technical Analysis & Stock Price Forecast - Intellectia AI
Analysts’ Top Healthcare Picks: Definium Therapeutics (DFTX), Lantheus (LNTH) - The Globe and Mail
Definium Therapeutics, Inc.Common Shares (NQ: DFTX - The Chronicle-Journal
Definium (DFTX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Definium Therapeutics Inc Azioni (DFTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):